Cargando…

Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment

Chronic myeloid leukemia (CML) is characterized by the constitutive tyrosine kinase activity of the oncoprotein BCR-ABL1 in myeloid progenitor cells that activates multiple signal transduction pathways leading to the leukemic phenotype. The tyrosine-kinase inhibitor (TKI) nilotinib inhibits the tyro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trojani, Alessandra, Pungolino, Ester, Dal Molin, Alessandra, Lodola, Milena, Rossi, Giuseppe, D’Adda, Mariella, Perego, Alessandra, Elena, Chiara, Turrini, Mauro, Borin, Lorenza, Bucelli, Cristina, Malato, Simona, Carraro, Maria Cristina, Spina, Francesco, Latargia, Maria Luisa, Artale, Salvatore, Spedini, Pierangelo, Anghilieri, Michela, Di Camillo, Barbara, Baruzzo, Giacomo, De Canal, Gabriella, Iurlo, Alessandra, Morra, Enrica, Cairoli, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6638825/ https://www.ncbi.nlm.nih.gov/pubmed/31318870 http://dx.doi.org/10.1371/journal.pone.0218444

Ejemplares similares

Nilotinib‐induced bone marrow CD34+/lin‐Ph+ cells early clearance in newly diagnosed CP‐Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study
por: Pungolino, Ester, et al.
Publicado: (2021)

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
por: Iurlo, Alessandra, et al.
Publicado: (2021)

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
por: Gemelli, Maria, et al.
Publicado: (2020)

Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
por: Pasquale, Raffaella, et al.
Publicado: (2022)

New Perspectives on Polycythemia Vera: From Diagnosis to Therapy
por: Iurlo, Alessandra, et al.
Publicado: (2020)

Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case
por: Bucelli, Cristina, et al.
Publicado: (2017)

Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience
por: Cattaneo, Daniele, et al.
Publicado: (2021)

Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer
por: Abruzzese, Elisabetta, et al.
Publicado: (2022)

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia
por: Galimberti, Sara, et al.
Publicado: (2017)

Trend of circulating CD34(+) cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment
por: Iurlo, Alessandra, et al.
Publicado: (2022)

Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization
por: L’Abbate, Alberto, et al.
Publicado: (2023)

Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review
por: Barozzi, Enrico, et al.
Publicado: (2022)

Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
por: Cutica, Ilaria, et al.
Publicado: (2022)

A Nine-Gene Expression Signature Distinguished a Patient with Chronic Lymphocytic Leukemia Who Underwent Prolonged Periodic Fasting
por: Bossi, Luca Emanuele, et al.
Publicado: (2023)

Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
por: Luciano, Luigia, et al.
Publicado: (2023)

Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
por: Iurlo, Alessandra, et al.
Publicado: (2015)

P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY
por: Paolo Maria Zambrotta, Giovanni, et al.
Publicado: (2023)

Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
por: Breccia, Massimo, et al.
Publicado: (2023)

Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance
por: Breccia, Massimo, et al.
Publicado: (2022)

Cordycepin (3′dA) Induces Cell Death of AC133(+) Leukemia Cells via Re-Expression of WIF1 and Down-Modulation of MYC
por: Abazari, Nazanin, et al.
Publicado: (2023)

An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review
por: Orofino, Nicola, et al.
Publicado: (2017)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Fludarabine in the treatment of chronic lymphocytic leukemia: a review
por: Ricci, Francesca, et al.
Publicado: (2009)

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2015)

Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia
por: Ricci, Francesca, et al.
Publicado: (2011)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

The spectrum of use of rituximab in chronic lymphocytic leukemia
por: Tedeschi, Alessandra, et al.
Publicado: (2010)

Reply to “COVID-19 in persons with haematological cancers”: a focus on myeloid neoplasms and risk factors for mortality
por: Fattizzo, Bruno, et al.
Publicado: (2020)

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
por: Alqasim, Alauldeen Mudhafar Zubair, et al.
Publicado: (2018)

Small-bowel myeloid sarcoma: Report of a case with atypical presentation
por: Girelli, Carlo M., et al.
Publicado: (2014)

Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells
por: Trojani, Alessandra, et al.
Publicado: (2021)

Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian Population
por: Abruzzese, Elisabetta, et al.
Publicado: (2019)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
por: DeRemer, David L, et al.
Publicado: (2011)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia
por: Al-Jafar, Hassan A., et al.
Publicado: (2015)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Montillo, Marco, et al.
Publicado: (2008)

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
por: Gugliotta, Gabriele, et al.
Publicado: (2022)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis
por: Cattaneo, Daniele, et al.
Publicado: (2022)

Single-Cell RNA-Sequencing: Assessment of Differential Expression Analysis Methods
por: Dal Molin, Alessandra, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lm1qft0lh909lifbh7c2kb2u96